$3.3 Million Bet On This Technology Stock? 3 Stocks Insiders Are Buying
$3.3 Million Bet On This Technology Stock? 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades.
尽管美国股市周一收盘走高，但仍有一些值得注意的内幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
当内部人士购买股票时，这表明他们对公司的前景充满信心，或者他们认为这只股票很划算。无论哪种方式，这都标志着做多该股的机会。内幕收购不应被视为做出投资或交易决定的唯一指标。充其量，它可以让买入决定更有说服力。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近几笔值得注意的内幕交易。欲了解更多信息，请查看Benzinga的内幕交易站台。
Ivanhoe Electric
艾芬豪电气
- The Trade: Ivanhoe Electric Inc. (NYSE:IE) CEO Robert M Friedland acquired a total of 416,666 shares an average price of $8.00. To acquire these shares, it cost around $3.33 million.
- What's Happening: JP Morgan, last month, initiated coverage on Ivanhoe Electric with a Neutral rating and announced a price target of $12.
- What Ivanhoe Electric Does: Ivanhoe Electric Inc is a mineral project exploration and development company with a focus on identifying and developing mineral projects, and ultimately mines, associated with the metals necessary for electrification, in particular, copper, gold, silver, nickel, cobalt, vanadium, and the platinum group metals.
- 行业： 艾芬豪电气公司(纽约证券交易所股票代码：IE)首席执行官罗伯特·M·弗里德兰共购入416,666股平均价格为8美元。收购这些股份的成本约为333万美元。
- 正在发生的事情：上个月，摩根大通(JP Morgan)对艾芬豪电气(Ivanhoe Electric)发起了中性评级，并宣布目标价为12美元。
- 艾芬豪电气的业务：艾芬豪电气公司是一家矿产项目勘探和开发公司，专注于识别和开发矿产项目，并最终开发与电气化所需的金属相关的矿产项目，特别是铜、金、银、镍、钴、钒和铂族金属。
Third Harmonic Bio
三次谐音生物
- The Trade: Third Harmonic Bio, Inc. (NASDAQ:THRD) 10% owner Atlas Venture Associates Opportunity I, LLC acquired a total of 7,366,470 shares at an average price of $17.00. To acquire these shares, it cost around $5.1 million.
- What's Happening: The company recently priced its IPO at $17 per share.
- What Third Harmonic Bio Does: Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation.
- 行业： 第三谐音生物公司。(纳斯达克：TRRD)10%股权阿特拉斯风险投资公司机会I，有限责任公司共购入7,366,470股平均价格为17.00美元。收购这些股份的成本约为510万美元。
- 正在发生的事情：该公司最近将首次公开募股(IPO)定价为每股17美元。
- Third Harmonic Bio的用途：Third Harmonic Bio Inc.是一家临床阶段的公司，正在开发一种治疗严重过敏和炎症的新的口服方法。
Don't forget to check out our premarket coverage here .
别忘了在这里查看我们的售前报道。
Also check this: Dow, Nasdaq Futures Lower Ahead Of Fed Meeting
另请查看：道琼斯指数，纳斯达克期货在美联储会议前下跌
Spok Holdings
SPOK控股
- The Trade: Spok Holdings, Inc. (NASDAQ:SPOK) Director Todd J Stein bought a total of 139,704 shares at an average price of $7.29. To acquire these shares, it cost around $1.02 million.
- What's Happening: The company's stock tumbled around 11% over the past six months.
- What Spok Holdings Does: Spok Holdings Inc is a provider of healthcare communications. It reports three market segments namely Healthcare, Government, and Large enterprise .
- 行业： SPOK控股公司(纳斯达克：SPOK)董事托德·J·斯坦共买入139,704股平均价格为7.29美元。收购这些股份的成本约为102万美元。
- 正在发生的事情：该公司的股票在过去六个月里暴跌了约11%。
- Spok Holdings的业务：SPOK控股公司是一家医疗保健通信提供商。它报告了三个细分市场，即医疗保健、政府和大型企业。
译文内容由第三方软件翻译。